Results 21 to 30 of about 164 (114)

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA

open access: yes, 2022
HemaSphere, Volume 6, Issue S3, Page 126-127, June 2022.
M. C. Pirosa   +41 more
wiley   +1 more source

Detection and characterization of lung cancer using cell-free DNA fragmentomes [PDF]

open access: yesNature Communications, 2021
AbstractNon-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection
Dimitrios Mathios   +37 more
openaire   +6 more sources

Long circulating-free DNA fragments predict early-progression (EP) and progression-free-survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): a new biomarker

open access: yes
International audienceBackgroundEstablishing reliable and early predictive biomarkers of response of ICI is essential. Analysis of cfDNA fragmentation profiles (fragmentome) is a promising non-invasive method to do so independently of a specific ...
Boutonnet, Audrey   +8 more
core   +4 more sources

Fragmentomics of natural peptide structures

open access: yesBiochemistry (Moscow), 2009
Natural fragmentation of peptide and other chemical structures is well known. They are a significant object of biochemical investigations. In this connection, the bases and determination are given for the notion of the "fragmentome" as a set of all fragments of a single substance, as well as for global fragmentome of all chemical components of living ...
openaire   +4 more sources

AGE-ASSOCIATED VARIABILITY OF CIRCULATING FREE DNA CHARACTERISTICS: GENOME-WIDE ANALYSIS

open access: yesJournal of Bioinformatics and Genomics
The fragments of circulating free DNA (cfDNA) found in plasma are formed due to the genomic DNA degradation during cellular death. The present study is the first research of age-associated variability of cfDNA characteristics performed on the group of ...
Meshkov I.O.   +13 more
doaj   +1 more source

Fragmentomics features of ovarian cancer

open access: yesInternational Journal of Cancer
AbstractOvarian cancer (OC) is a major cause of cancer mortality in women worldwide. Due to the occult onset of OC, its nonspecific clinical symptoms in the early phase, and a lack of effective early diagnostic tools, most OC patients are diagnosed at an advanced stage.
Xiaopei Chao   +11 more
openaire   +2 more sources

Diagnostics of lung cancer by fragmentated blood circulating cell-free DNA based on machine learning methods

open access: yesFrontiers in Medicine
IntroductionMinimally invasive diagnostics based on liquid biopsy makes it possible early detection of lung cancer (LC). The blood plasma circulating cell-free DNA (cfDNA) fragments reflect the genome and chromatin status and are considered as integral ...
Ivan O. Meshkov   +17 more
doaj   +1 more source

Cell-free DNA fragmentomics in cancer

open access: yesCancer Cell
The analysis of cell-free DNA (cfDNA) fragmentation patterns, known as "fragmentomics," has opened new opportunities in noninvasive cancer diagnostics. Due to its close relationships with genomic organization and cell death, cfDNA fragmentomics lies at the intersection of many aspects of cancer biology, including epigenetic dysregulation ...
W H Adrian, Tsui   +2 more
openaire   +2 more sources

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

open access: yesInternational Journal of Cancer, Volume 158, Issue 10, Page 2771-2783, 15 May 2026.
What's New? Circulating nuclear DNA (cir‐nDNA)‐based assessment of minimal residual disease (MRD) offers powerful post‐surgery prognostic insight for stage III colon cancer (CC). Sparse knowledge of post‐surgical variations and origins in cir‐nDNA, however, has limited its clinical application.
Andrei Kudriavtsev   +17 more
wiley   +1 more source

Abstracts

open access: yes, 2023
Molecular Oncology, Volume 17, Issue S1, Page 1-597, June 2023.
wiley   +1 more source

Home - About - Disclaimer - Privacy